- Home
- PNNT vs PRQR Comparison
PNNT vs PRQR Comparison
Compare PNNT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNNT | PRQR |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 244.1M |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PNNT | PRQR |
|---|---|---|
| Price | $3.42 | $1.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $5.75 | ★ $7.25 |
| AVG Volume (30 Days) | 821.2K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 20.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $1.33 |
| 52 Week High | $7.53 | $3.10 |
Technical Indicators
Market Signals| Indicator | PNNT | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 51.87 |
| Support Level | $3.30 | $1.40 |
| Resistance Level | $3.59 | $2.03 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 41.38 | 61.34 |
Price Performance
Historical ComparisonAbout PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.